Showing results (381-390 of 682) with videos related to

Sort By:
Pageof 69
Cancer Research|October 3, 2003
The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma modelBlake Lee Neubauer, Ann M McNulty, Marcio Chedid, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 26, 2014
A review of the application of inflammatory biomarkers in epidemiologic cancer researchDarren R Brenner, Dominique Scherer, Kenneth Muir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2017
Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical OutcomesChen Wang, Sebastian M Armasu, Kimberly R Kalli, et al.
Plos One|March 30, 2011
Salmonella phage ST64B encodes a member of the SseK/NleB effector familyNat F Brown, Brian K Coombes, Jenna L Bishop, et al.
The Prostate|October 1, 1995
Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma modelB L Neubauer, K L Best, D F Counts, et al.
Gynecologic Oncology|May 8, 2009
Polymorphisms in TCEAL7 and risk of epithelial ovarian cancerAbraham Peedicayil, Robert A Vierkant, Vijayalakshmi Shridhar, et al.
Nature|February 19, 2011
Coronin 2A mediates actin-dependent de-repression of inflammatory response genesWendy Huang, Serena Ghisletti, Kaoru Saijo, et al.
The Prostate|January 1, 1993
Endocrine and antiprostatic effects of raloxifene (LY156758) in the male ratB L Neubauer, K L Best, J A Clemens, et al.
Genes & Cancer|July 26, 2017
EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature reviewChristine Mehner, Ann L Oberg, Krista M Goergen, et al.
The Journal of Steroid Biochemistry and Molecular Biology|May 1, 1996
Characterization of type I 5 alpha-reductase activity in DU145 human prostatic adenocarcinoma cellsM Kaefer, J E Audia, N Bruchovsky, et al.
Pageof 69